| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Marijuana Abuse | 35 | 2022 | 251 | 11.610 |
Why?
|
| Acetylcysteine | 22 | 2021 | 296 | 7.770 |
Why?
|
| Smoking Cessation | 37 | 2023 | 1032 | 6.430 |
Why?
|
| Tobacco Use Disorder | 21 | 2023 | 432 | 4.960 |
Why?
|
| Smoking | 30 | 2021 | 1449 | 4.420 |
Why?
|
| Substance-Related Disorders | 17 | 2022 | 1242 | 4.010 |
Why?
|
| Cannabis | 13 | 2023 | 115 | 3.900 |
Why?
|
| Marijuana Smoking | 12 | 2020 | 108 | 3.790 |
Why?
|
| Varenicline | 13 | 2023 | 98 | 3.520 |
Why?
|
| Adolescent | 79 | 2023 | 8904 | 3.210 |
Why?
|
| Intellectual Disability | 8 | 2023 | 114 | 3.130 |
Why?
|
| Young Adult | 61 | 2023 | 5710 | 2.830 |
Why?
|
| Cigarette Smoking | 6 | 2023 | 104 | 2.810 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 8 | 2023 | 189 | 2.490 |
Why?
|
| Cues | 19 | 2022 | 654 | 2.430 |
Why?
|
| Behavior, Addictive | 10 | 2020 | 317 | 2.230 |
Why?
|
| Free Radical Scavengers | 7 | 2019 | 112 | 2.180 |
Why?
|
| Alcohol Drinking | 6 | 2020 | 805 | 2.110 |
Why?
|
| Substance Withdrawal Syndrome | 12 | 2019 | 435 | 2.010 |
Why?
|
| Female | 107 | 2023 | 38021 | 1.930 |
Why?
|
| Humans | 138 | 2023 | 68549 | 1.850 |
Why?
|
| Stress, Psychological | 11 | 2022 | 824 | 1.850 |
Why?
|
| Adult | 74 | 2023 | 21379 | 1.830 |
Why?
|
| Tobacco Products | 8 | 2021 | 234 | 1.810 |
Why?
|
| Male | 98 | 2022 | 37283 | 1.780 |
Why?
|
| Cannabinoids | 8 | 2022 | 90 | 1.780 |
Why?
|
| Nicotinic Agonists | 8 | 2015 | 111 | 1.730 |
Why?
|
| Social Environment | 4 | 2020 | 182 | 1.670 |
Why?
|
| Smokers | 10 | 2022 | 198 | 1.660 |
Why?
|
| Adolescent Behavior | 6 | 2020 | 264 | 1.640 |
Why?
|
| Double-Blind Method | 24 | 2023 | 1738 | 1.640 |
Why?
|
| Quinoxalines | 5 | 2015 | 78 | 1.560 |
Why?
|
| Patient Acceptance of Health Care | 5 | 2019 | 467 | 1.550 |
Why?
|
| Benzazepines | 5 | 2015 | 104 | 1.530 |
Why?
|
| Marijuana Use | 3 | 2020 | 35 | 1.410 |
Why?
|
| Autistic Disorder | 4 | 2022 | 77 | 1.360 |
Why?
|
| Nicotine | 8 | 2017 | 350 | 1.350 |
Why?
|
| Depression | 5 | 2019 | 942 | 1.290 |
Why?
|
| Treatment Outcome | 26 | 2023 | 7028 | 1.270 |
Why?
|
| Tobacco, Smokeless | 5 | 2017 | 40 | 1.220 |
Why?
|
| Counseling | 4 | 2019 | 279 | 1.200 |
Why?
|
| Menstrual Cycle | 5 | 2022 | 64 | 1.150 |
Why?
|
| Autism Spectrum Disorder | 4 | 2022 | 111 | 1.140 |
Why?
|
| Tobacco Use Cessation | 2 | 2023 | 44 | 1.060 |
Why?
|
| Research Design | 6 | 2021 | 729 | 1.060 |
Why?
|
| Adolescent Development | 4 | 2021 | 28 | 1.060 |
Why?
|
| Anxiety | 5 | 2021 | 422 | 1.060 |
Why?
|
| Self Report | 11 | 2022 | 370 | 1.060 |
Why?
|
| Impulsive Behavior | 3 | 2016 | 85 | 1.050 |
Why?
|
| Middle Aged | 40 | 2022 | 21119 | 1.000 |
Why?
|
| Medication Adherence | 6 | 2019 | 335 | 0.990 |
Why?
|
| Memory Disorders | 3 | 2015 | 111 | 0.970 |
Why?
|
| Craving | 7 | 2022 | 200 | 0.950 |
Why?
|
| Alcoholism | 4 | 2020 | 1109 | 0.880 |
Why?
|
| Progesterone | 4 | 2022 | 115 | 0.870 |
Why?
|
| Behavior Therapy | 6 | 2020 | 297 | 0.870 |
Why?
|
| Child | 25 | 2023 | 6401 | 0.870 |
Why?
|
| Motivation | 10 | 2020 | 561 | 0.870 |
Why?
|
| Absenteeism | 1 | 2023 | 27 | 0.870 |
Why?
|
| Brain | 9 | 2021 | 2176 | 0.860 |
Why?
|
| Magnetic Resonance Imaging | 10 | 2021 | 2222 | 0.790 |
Why?
|
| Ecological Momentary Assessment | 2 | 2018 | 16 | 0.770 |
Why?
|
| Dronabinol | 5 | 2019 | 84 | 0.770 |
Why?
|
| Sex Factors | 9 | 2020 | 1265 | 0.760 |
Why?
|
| Bupropion | 2 | 2011 | 63 | 0.750 |
Why?
|
| Age Factors | 8 | 2020 | 1860 | 0.720 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2020 | 1745 | 0.720 |
Why?
|
| Pilot Projects | 14 | 2022 | 1341 | 0.720 |
Why?
|
| Sports | 1 | 2020 | 55 | 0.720 |
Why?
|
| Estradiol | 4 | 2021 | 176 | 0.710 |
Why?
|
| Family Characteristics | 1 | 2020 | 44 | 0.700 |
Why?
|
| Neuroimaging | 2 | 2021 | 122 | 0.700 |
Why?
|
| Smoking Devices | 1 | 2019 | 6 | 0.690 |
Why?
|
| Luteal Phase | 4 | 2022 | 25 | 0.670 |
Why?
|
| False Negative Reactions | 1 | 2019 | 63 | 0.660 |
Why?
|
| Intimate Partner Violence | 1 | 2020 | 58 | 0.660 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2021 | 929 | 0.640 |
Why?
|
| Substance Abuse Detection | 3 | 2018 | 66 | 0.630 |
Why?
|
| Follicular Phase | 3 | 2015 | 15 | 0.620 |
Why?
|
| Employment | 2 | 2022 | 154 | 0.600 |
Why?
|
| Health Services Research | 1 | 2019 | 209 | 0.600 |
Why?
|
| Australia | 3 | 2023 | 235 | 0.580 |
Why?
|
| Down Syndrome | 2 | 2016 | 120 | 0.570 |
Why?
|
| Crime Victims | 1 | 2020 | 286 | 0.570 |
Why?
|
| Sensation | 1 | 2016 | 49 | 0.550 |
Why?
|
| Underage Drinking | 1 | 2016 | 25 | 0.550 |
Why?
|
| Mobile Applications | 1 | 2018 | 138 | 0.540 |
Why?
|
| Developmental Disabilities | 3 | 2021 | 119 | 0.530 |
Why?
|
| Hallucinogens | 2 | 2022 | 14 | 0.530 |
Why?
|
| Psychomotor Performance | 2 | 2015 | 213 | 0.520 |
Why?
|
| Precision Medicine | 1 | 2016 | 111 | 0.510 |
Why?
|
| Sleep | 1 | 2017 | 263 | 0.510 |
Why?
|
| Antioxidants | 1 | 2017 | 304 | 0.500 |
Why?
|
| Cognition Disorders | 2 | 2015 | 342 | 0.500 |
Why?
|
| Frontal Lobe | 2 | 2015 | 156 | 0.500 |
Why?
|
| Suicide | 1 | 2016 | 115 | 0.500 |
Why?
|
| Arousal | 5 | 2014 | 168 | 0.490 |
Why?
|
| Exercise | 1 | 2020 | 658 | 0.490 |
Why?
|
| Parents | 5 | 2023 | 309 | 0.490 |
Why?
|
| Neural Pathways | 2 | 2015 | 323 | 0.480 |
Why?
|
| Cognitive Dysfunction | 1 | 2017 | 176 | 0.470 |
Why?
|
| Smoking Prevention | 6 | 2018 | 259 | 0.470 |
Why?
|
| Education of Intellectually Disabled | 1 | 2013 | 4 | 0.460 |
Why?
|
| Corpus Striatum | 1 | 2015 | 278 | 0.460 |
Why?
|
| Combined Modality Therapy | 7 | 2020 | 951 | 0.450 |
Why?
|
| Rehabilitation, Vocational | 1 | 2013 | 14 | 0.450 |
Why?
|
| Electronic Nicotine Delivery Systems | 3 | 2022 | 180 | 0.450 |
Why?
|
| Community Participation | 1 | 2013 | 42 | 0.440 |
Why?
|
| Cognition | 6 | 2021 | 512 | 0.430 |
Why?
|
| Excitatory Amino Acid Agonists | 1 | 2012 | 59 | 0.430 |
Why?
|
| Heart Rate | 6 | 2015 | 568 | 0.420 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2012 | 128 | 0.400 |
Why?
|
| Reproducibility of Results | 6 | 2019 | 2077 | 0.390 |
Why?
|
| Comorbidity | 5 | 2019 | 1425 | 0.390 |
Why?
|
| Mental Disorders | 4 | 2021 | 659 | 0.390 |
Why?
|
| Diagnosis, Dual (Psychiatry) | 2 | 2016 | 151 | 0.390 |
Why?
|
| Residence Characteristics | 1 | 2013 | 252 | 0.390 |
Why?
|
| Adaptation, Psychological | 1 | 2014 | 447 | 0.390 |
Why?
|
| Child, Preschool | 10 | 2021 | 3187 | 0.380 |
Why?
|
| Longitudinal Studies | 7 | 2021 | 1054 | 0.370 |
Why?
|
| Sex Characteristics | 4 | 2020 | 295 | 0.360 |
Why?
|
| Ganglionic Stimulants | 1 | 2009 | 15 | 0.350 |
Why?
|
| Central Nervous System Stimulants | 4 | 2019 | 221 | 0.350 |
Why?
|
| Drug Therapy | 1 | 2009 | 71 | 0.330 |
Why?
|
| Dopamine Uptake Inhibitors | 1 | 2010 | 152 | 0.330 |
Why?
|
| Quality of Life | 1 | 2017 | 1515 | 0.330 |
Why?
|
| Cannabidiol | 2 | 2021 | 31 | 0.330 |
Why?
|
| Conditioning, Operant | 1 | 2010 | 241 | 0.320 |
Why?
|
| Aging | 1 | 2014 | 911 | 0.320 |
Why?
|
| Prevalence | 4 | 2020 | 1609 | 0.320 |
Why?
|
| Tobacco Smoking | 2 | 2020 | 41 | 0.320 |
Why?
|
| Therapy, Computer-Assisted | 2 | 2019 | 57 | 0.310 |
Why?
|
| Avoidance Learning | 2 | 2019 | 58 | 0.310 |
Why?
|
| Parenting | 2 | 2021 | 91 | 0.310 |
Why?
|
| Neuropsychological Tests | 4 | 2015 | 517 | 0.300 |
Why?
|
| Caregivers | 4 | 2022 | 365 | 0.300 |
Why?
|
| Affect | 4 | 2015 | 218 | 0.300 |
Why?
|
| Patient Compliance | 3 | 2019 | 402 | 0.300 |
Why?
|
| Gonadal Steroid Hormones | 2 | 2021 | 52 | 0.290 |
Why?
|
| Galvanic Skin Response | 4 | 2010 | 67 | 0.280 |
Why?
|
| Saliva | 3 | 2022 | 142 | 0.270 |
Why?
|
| United States | 8 | 2020 | 7338 | 0.260 |
Why?
|
| Cross-Sectional Studies | 6 | 2021 | 2265 | 0.260 |
Why?
|
| Feasibility Studies | 3 | 2022 | 652 | 0.260 |
Why?
|
| Follow-Up Studies | 6 | 2019 | 3256 | 0.260 |
Why?
|
| Clinical Trials as Topic | 3 | 2020 | 848 | 0.260 |
Why?
|
| Iron | 2 | 2019 | 197 | 0.250 |
Why?
|
| Stress Disorders, Post-Traumatic | 3 | 2021 | 1506 | 0.250 |
Why?
|
| Psychiatric Status Rating Scales | 3 | 2017 | 782 | 0.250 |
Why?
|
| Memory | 4 | 2015 | 214 | 0.240 |
Why?
|
| Surveys and Questionnaires | 7 | 2015 | 2798 | 0.240 |
Why?
|
| Behavioral Symptoms | 2 | 2017 | 32 | 0.240 |
Why?
|
| Practice Guidelines as Topic | 1 | 2009 | 772 | 0.240 |
Why?
|
| Administration, Oral | 3 | 2015 | 411 | 0.230 |
Why?
|
| South Carolina | 4 | 2020 | 2752 | 0.230 |
Why?
|
| Hydrocortisone | 2 | 2022 | 291 | 0.220 |
Why?
|
| Risk Factors | 7 | 2021 | 5720 | 0.220 |
Why?
|
| Product Labeling | 2 | 2013 | 43 | 0.220 |
Why?
|
| Drug Administration Schedule | 2 | 2014 | 567 | 0.210 |
Why?
|
| Mass Media | 1 | 2021 | 29 | 0.200 |
Why?
|
| Medical Marijuana | 2 | 2018 | 21 | 0.200 |
Why?
|
| Mass Screening | 1 | 2007 | 838 | 0.200 |
Why?
|
| Biomarkers | 5 | 2018 | 1593 | 0.200 |
Why?
|
| Multimodal Imaging | 2 | 2019 | 62 | 0.200 |
Why?
|
| Cyclonic Storms | 1 | 2021 | 58 | 0.200 |
Why?
|
| Recurrence | 3 | 2019 | 948 | 0.190 |
Why?
|
| Oxytocin | 2 | 2020 | 124 | 0.190 |
Why?
|
| Puberty | 1 | 2021 | 10 | 0.190 |
Why?
|
| Sexual Maturation | 1 | 2021 | 10 | 0.190 |
Why?
|
| Telemedicine | 2 | 2022 | 699 | 0.190 |
Why?
|
| Time Factors | 4 | 2018 | 4655 | 0.190 |
Why?
|
| Intention | 2 | 2013 | 78 | 0.190 |
Why?
|
| Students | 1 | 2023 | 233 | 0.190 |
Why?
|
| Delayed-Action Preparations | 2 | 2011 | 120 | 0.180 |
Why?
|
| Child Development | 1 | 2021 | 102 | 0.180 |
Why?
|
| Predictive Value of Tests | 2 | 2017 | 1465 | 0.180 |
Why?
|
| Drug Users | 1 | 2020 | 10 | 0.180 |
Why?
|
| Patient Outcome Assessment | 1 | 2020 | 42 | 0.180 |
Why?
|
| Drug Monitoring | 1 | 2020 | 107 | 0.180 |
Why?
|
| Vaping | 1 | 2022 | 124 | 0.170 |
Why?
|
| Attention Deficit and Disruptive Behavior Disorders | 1 | 2019 | 29 | 0.170 |
Why?
|
| Linear Models | 2 | 2019 | 521 | 0.170 |
Why?
|
| Health Status Disparities | 2 | 2013 | 326 | 0.170 |
Why?
|
| Retrospective Studies | 3 | 2020 | 7268 | 0.170 |
Why?
|
| Mindfulness | 1 | 2019 | 41 | 0.170 |
Why?
|
| Brain Mapping | 2 | 2019 | 531 | 0.160 |
Why?
|
| Racism | 1 | 2019 | 59 | 0.160 |
Why?
|
| Stress, Physiological | 1 | 2020 | 215 | 0.160 |
Why?
|
| Family Therapy | 1 | 2019 | 82 | 0.160 |
Why?
|
| Legislation, Drug | 1 | 2018 | 9 | 0.160 |
Why?
|
| Severity of Illness Index | 5 | 2014 | 1851 | 0.160 |
Why?
|
| Personal Satisfaction | 1 | 2019 | 123 | 0.160 |
Why?
|
| Breath Tests | 1 | 2018 | 23 | 0.160 |
Why?
|
| Child Health | 1 | 2018 | 15 | 0.160 |
Why?
|
| Gender Identity | 2 | 2015 | 47 | 0.160 |
Why?
|
| Proof of Concept Study | 1 | 2018 | 38 | 0.160 |
Why?
|
| Functional Neuroimaging | 2 | 2021 | 82 | 0.160 |
Why?
|
| Wearable Electronic Devices | 1 | 2018 | 16 | 0.150 |
Why?
|
| Carbon Monoxide | 1 | 2018 | 58 | 0.150 |
Why?
|
| Behavior Rating Scale | 1 | 2017 | 7 | 0.150 |
Why?
|
| Sulpiride | 1 | 2017 | 20 | 0.150 |
Why?
|
| Exercise Therapy | 1 | 2019 | 183 | 0.150 |
Why?
|
| Ambulatory Care | 1 | 2020 | 339 | 0.150 |
Why?
|
| Smartphone | 1 | 2018 | 69 | 0.150 |
Why?
|
| Tobacco Use | 1 | 2018 | 98 | 0.150 |
Why?
|
| Women's Health | 2 | 2015 | 148 | 0.150 |
Why?
|
| Help-Seeking Behavior | 1 | 2017 | 13 | 0.150 |
Why?
|
| Child Behavior Disorders | 1 | 2017 | 69 | 0.150 |
Why?
|
| Psychopathology | 1 | 2017 | 29 | 0.150 |
Why?
|
| Cocaine | 1 | 2022 | 555 | 0.140 |
Why?
|
| Social Media | 1 | 2018 | 58 | 0.140 |
Why?
|
| Patient Care Management | 1 | 2017 | 40 | 0.140 |
Why?
|
| Object Attachment | 1 | 2016 | 20 | 0.140 |
Why?
|
| Thalamus | 1 | 2017 | 82 | 0.140 |
Why?
|
| Perception | 1 | 2017 | 189 | 0.140 |
Why?
|
| Neural Inhibition | 1 | 2017 | 80 | 0.140 |
Why?
|
| Biomedical Research | 1 | 2020 | 310 | 0.140 |
Why?
|
| Public Health | 1 | 2018 | 201 | 0.140 |
Why?
|
| Data Collection | 1 | 2018 | 420 | 0.140 |
Why?
|
| Attention | 2 | 2016 | 225 | 0.140 |
Why?
|
| Behavioral Research | 1 | 2016 | 10 | 0.140 |
Why?
|
| Vilazodone Hydrochloride | 1 | 2015 | 6 | 0.130 |
Why?
|
| Combat Disorders | 1 | 2016 | 102 | 0.130 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2019 | 689 | 0.130 |
Why?
|
| Serotonin Receptor Agonists | 1 | 2015 | 34 | 0.130 |
Why?
|
| Buspirone | 1 | 2015 | 36 | 0.130 |
Why?
|
| Transdermal Patch | 1 | 2015 | 21 | 0.130 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2017 | 333 | 0.130 |
Why?
|
| Nerve Net | 1 | 2017 | 180 | 0.130 |
Why?
|
| Patient Selection | 1 | 2019 | 592 | 0.120 |
Why?
|
| National Institute on Drug Abuse (U.S.) | 1 | 2014 | 19 | 0.120 |
Why?
|
| Incidence | 1 | 2019 | 1582 | 0.120 |
Why?
|
| Prospective Studies | 5 | 2021 | 3703 | 0.120 |
Why?
|
| Risk | 1 | 2016 | 563 | 0.120 |
Why?
|
| Reward | 1 | 2016 | 201 | 0.120 |
Why?
|
| Memory, Short-Term | 1 | 2015 | 79 | 0.120 |
Why?
|
| Primary Health Care | 1 | 2020 | 702 | 0.120 |
Why?
|
| Databases, Factual | 1 | 2017 | 621 | 0.120 |
Why?
|
| Executive Function | 1 | 2015 | 106 | 0.120 |
Why?
|
| Cerebral Cortex | 1 | 2017 | 415 | 0.120 |
Why?
|
| Nitrosamines | 1 | 2013 | 18 | 0.120 |
Why?
|
| New South Wales | 1 | 2013 | 10 | 0.110 |
Why?
|
| Hotlines | 1 | 2014 | 51 | 0.110 |
Why?
|
| Administration, Cutaneous | 1 | 2013 | 56 | 0.110 |
Why?
|
| Molecular Structure | 2 | 2014 | 397 | 0.110 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2014 | 137 | 0.110 |
Why?
|
| Data Interpretation, Statistical | 2 | 2021 | 329 | 0.110 |
Why?
|
| Genetic Testing | 1 | 2014 | 159 | 0.110 |
Why?
|
| Veterans | 2 | 2020 | 904 | 0.110 |
Why?
|
| Propranolol | 1 | 2013 | 102 | 0.110 |
Why?
|
| Weight Reduction Programs | 1 | 2013 | 67 | 0.110 |
Why?
|
| Ovary | 1 | 2012 | 99 | 0.100 |
Why?
|
| Prognosis | 1 | 2017 | 2093 | 0.100 |
Why?
|
| Life Style | 1 | 2013 | 338 | 0.100 |
Why?
|
| Nausea | 1 | 2011 | 47 | 0.100 |
Why?
|
| Nootropic Agents | 1 | 2011 | 18 | 0.100 |
Why?
|
| Diagnosis-Related Groups | 1 | 2011 | 28 | 0.100 |
Why?
|
| Algorithms | 2 | 2007 | 1195 | 0.090 |
Why?
|
| Analysis of Variance | 1 | 2013 | 1040 | 0.090 |
Why?
|
| Hypothalamo-Hypophyseal System | 2 | 2022 | 150 | 0.090 |
Why?
|
| Pituitary-Adrenal System | 2 | 2022 | 138 | 0.090 |
Why?
|
| Placebos | 1 | 2011 | 195 | 0.090 |
Why?
|
| Risk Assessment | 1 | 2017 | 2004 | 0.090 |
Why?
|
| Health Behavior | 2 | 2014 | 458 | 0.090 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2011 | 91 | 0.090 |
Why?
|
| Methylphenidate | 1 | 2011 | 97 | 0.090 |
Why?
|
| Administration, Intranasal | 2 | 2020 | 88 | 0.090 |
Why?
|
| Imagination | 1 | 2008 | 38 | 0.080 |
Why?
|
| Euphoria | 1 | 2008 | 1 | 0.080 |
Why?
|
| Self Efficacy | 1 | 2010 | 199 | 0.080 |
Why?
|
| Infant | 2 | 2007 | 2891 | 0.080 |
Why?
|
| Aged | 5 | 2020 | 14842 | 0.080 |
Why?
|
| Cocaine-Related Disorders | 1 | 2013 | 504 | 0.080 |
Why?
|
| Personality Assessment | 1 | 2007 | 71 | 0.080 |
Why?
|
| Disease Progression | 1 | 2011 | 1037 | 0.070 |
Why?
|
| Early Diagnosis | 1 | 2007 | 122 | 0.070 |
Why?
|
| Socioeconomic Factors | 2 | 2021 | 955 | 0.070 |
Why?
|
| Observer Variation | 1 | 2007 | 330 | 0.070 |
Why?
|
| Child Development Disorders, Pervasive | 1 | 2006 | 26 | 0.070 |
Why?
|
| Blood Pressure | 2 | 2013 | 1449 | 0.070 |
Why?
|
| ROC Curve | 1 | 2007 | 392 | 0.070 |
Why?
|
| Cardiovascular Diseases | 1 | 2013 | 938 | 0.070 |
Why?
|
| Mood Disorders | 1 | 2006 | 132 | 0.060 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 1 | 2006 | 257 | 0.060 |
Why?
|
| Family | 1 | 2006 | 293 | 0.060 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2010 | 766 | 0.060 |
Why?
|
| Sensitivity and Specificity | 1 | 2007 | 1753 | 0.060 |
Why?
|
| Cannabinoid Receptor Agonists | 1 | 2022 | 20 | 0.050 |
Why?
|
| Tobacco | 1 | 2023 | 161 | 0.050 |
Why?
|
| Environment | 1 | 2022 | 115 | 0.050 |
Why?
|
| Telephone | 2 | 2014 | 160 | 0.050 |
Why?
|
| Social Behavior Disorders | 1 | 2001 | 16 | 0.050 |
Why?
|
| Case-Control Studies | 2 | 2016 | 1549 | 0.050 |
Why?
|
| Dehydroepiandrosterone | 1 | 2021 | 29 | 0.050 |
Why?
|
| Florida | 1 | 2021 | 221 | 0.050 |
Why?
|
| Incidental Findings | 1 | 2021 | 42 | 0.050 |
Why?
|
| Gyrus Cinguli | 1 | 2021 | 113 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2021 | 2356 | 0.050 |
Why?
|
| Testosterone | 1 | 2021 | 96 | 0.050 |
Why?
|
| Neuroendocrine Cells | 1 | 2020 | 8 | 0.050 |
Why?
|
| Neurosecretory Systems | 1 | 2020 | 21 | 0.050 |
Why?
|
| Amygdala | 1 | 2021 | 159 | 0.040 |
Why?
|
| Risk Reduction Behavior | 1 | 2021 | 174 | 0.040 |
Why?
|
| Bias | 1 | 2019 | 148 | 0.040 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2019 | 100 | 0.040 |
Why?
|
| Anxiety Disorders | 1 | 2021 | 426 | 0.040 |
Why?
|
| Referral and Consultation | 1 | 2021 | 383 | 0.040 |
Why?
|
| Photic Stimulation | 1 | 2019 | 229 | 0.040 |
Why?
|
| Research | 1 | 2019 | 214 | 0.040 |
Why?
|
| Hippocampus | 1 | 2021 | 471 | 0.040 |
Why?
|
| California | 1 | 2018 | 99 | 0.040 |
Why?
|
| Problem Behavior | 1 | 2017 | 20 | 0.040 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2019 | 239 | 0.040 |
Why?
|
| Video Recording | 1 | 2018 | 145 | 0.040 |
Why?
|
| Patient Satisfaction | 1 | 2020 | 378 | 0.040 |
Why?
|
| Checklist | 1 | 2017 | 76 | 0.040 |
Why?
|
| Statistics as Topic | 1 | 2017 | 219 | 0.030 |
Why?
|
| Animals | 1 | 2014 | 20880 | 0.030 |
Why?
|
| Behavior | 1 | 2016 | 59 | 0.030 |
Why?
|
| Luteinizing Hormone | 1 | 2016 | 31 | 0.030 |
Why?
|
| Parent-Child Relations | 1 | 2016 | 98 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2016 | 216 | 0.030 |
Why?
|
| Receptor, Serotonin, 5-HT1A | 1 | 2015 | 11 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2016 | 272 | 0.030 |
Why?
|
| Motivational Interviewing | 1 | 2015 | 40 | 0.030 |
Why?
|
| Synaptic Transmission | 1 | 2017 | 236 | 0.030 |
Why?
|
| Psychiatry | 1 | 2016 | 112 | 0.030 |
Why?
|
| Emotions | 1 | 2016 | 244 | 0.030 |
Why?
|
| Health Services Accessibility | 1 | 2019 | 581 | 0.030 |
Why?
|
| Echo-Planar Imaging | 1 | 2014 | 17 | 0.030 |
Why?
|
| Alleles | 1 | 2015 | 386 | 0.030 |
Why?
|
| Affinity Labels | 1 | 1994 | 66 | 0.030 |
Why?
|
| Bacteriorhodopsins | 1 | 1994 | 47 | 0.030 |
Why?
|
| Self Administration | 1 | 2015 | 419 | 0.030 |
Why?
|
| Fasting | 1 | 2013 | 75 | 0.030 |
Why?
|
| Light | 1 | 1994 | 152 | 0.030 |
Why?
|
| Triglycerides | 1 | 2013 | 184 | 0.030 |
Why?
|
| Psychotherapy | 1 | 2015 | 253 | 0.030 |
Why?
|
| Product Packaging | 1 | 2012 | 17 | 0.030 |
Why?
|
| Health Literacy | 1 | 2012 | 62 | 0.030 |
Why?
|
| Cholesterol | 1 | 2013 | 331 | 0.030 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2013 | 189 | 0.030 |
Why?
|
| Models, Molecular | 1 | 1994 | 546 | 0.030 |
Why?
|
| Adrenergic Agents | 1 | 2011 | 14 | 0.020 |
Why?
|
| Prefrontal Cortex | 1 | 2017 | 639 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2013 | 502 | 0.020 |
Why?
|
| Excitatory Amino Acid Agents | 1 | 2011 | 20 | 0.020 |
Why?
|
| Weight Loss | 1 | 2013 | 319 | 0.020 |
Why?
|
| Learning | 1 | 2013 | 186 | 0.020 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2011 | 58 | 0.020 |
Why?
|
| Benzhydryl Compounds | 1 | 2011 | 62 | 0.020 |
Why?
|
| Neurotransmitter Agents | 1 | 2011 | 102 | 0.020 |
Why?
|
| Health Policy | 1 | 2012 | 221 | 0.020 |
Why?
|
| Cotinine | 1 | 2010 | 40 | 0.020 |
Why?
|
| Blood Glucose | 1 | 2013 | 631 | 0.020 |
Why?
|
| Self Disclosure | 1 | 2010 | 55 | 0.020 |
Why?
|
| Wechsler Scales | 1 | 2006 | 15 | 0.020 |
Why?
|
| Psychological Tests | 1 | 2006 | 96 | 0.020 |
Why?
|
| Psychometrics | 1 | 2009 | 514 | 0.020 |
Why?
|
| Cost of Illness | 1 | 2006 | 204 | 0.020 |
Why?
|
| Reality Testing | 1 | 1981 | 2 | 0.010 |
Why?
|
| Methods | 1 | 1981 | 156 | 0.010 |
Why?
|
| Orientation | 1 | 1981 | 31 | 0.010 |
Why?
|
| Time | 1 | 1981 | 57 | 0.010 |
Why?
|
| Mental Recall | 1 | 1981 | 72 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1994 | 219 | 0.010 |
Why?
|
| Protein Structure, Secondary | 1 | 1994 | 136 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 1994 | 1082 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 1994 | 1446 | 0.010 |
Why?
|